GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Shares Outstanding (EOP)

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Shares Outstanding (EOP) : 23.75 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. IPI Legacy Liquidation Co's shares outstanding for the quarter that ended in Sep. 2023 was 23.75 Mil.

IPI Legacy Liquidation Co's quarterly shares outstanding stayed the same from Jun. 2023 (23.75 Mil) to Sep. 2023 (23.75 Mil).

IPI Legacy Liquidation Co's annual shares outstanding increased from Dec. 2021 (23.12 Mil) to Dec. 2022 (23.74 Mil). It means IPI Legacy Liquidation Co issued new shares from Dec. 2021 to Dec. 2022 .


IPI Legacy Liquidation Co Shares Outstanding (EOP) Historical Data

The historical data trend for IPI Legacy Liquidation Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Shares Outstanding (EOP) Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
13.14 19.41 23.12 23.74

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.74 23.74 23.75 23.75 23.75

Competitive Comparison of IPI Legacy Liquidation Co's Shares Outstanding (EOP)

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Shares Outstanding (EOP) falls into.



IPI Legacy Liquidation Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


IPI Legacy Liquidation Co  (OTCPK:IMPLQ) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


IPI Legacy Liquidation Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Headlines

From GuruFocus